Your session is about to expire
← Back to Search
Galcanezumab Prefilled Syringe for Vestibular Migraine
Study Summary
This trial is testing whether Galcanezumab, a drug used to treat migraines, can also help treat vestibular migraines. Vestibular migraines are a type of migraine that mainly causes dizziness.
- Vestibular Migraine
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Could you provide figures on how many individuals are being welcomed into this investigation?
"That is correct, the online information says that this trial is still looking for patients. This clinical trial was first posted on September 18th 2020 and was updated most recently on March 21st 2022. The study is looking for 50 people to participate at 1 location."
Could you please provide a rundown of other research that has been done on Galcanezumab Prefilled Syringe?
"Given that there are 6 ongoing trials and 2 in Phase 3, Galcanezumab Prefilled Syringe is currently being heavily studied. The majority of these trials are based in Brookline, Massachusetts, but there are also 330 other locations running these trials."
Have similar studies been conducted before this one?
"Galcanezumab Prefilled Syringe has undergone 6 clinical trials in 11 countries and 141 cities since 2018. The first Phase 3 drug approval stage for Galcanezumab Prefilled Syringe was completed in 2018 by Eli Lilly and Company. Since then, 18250 trials have been conducted."
Does this research project focus on a specific age group?
"This clinical trial's age requirements for participants are between 18 and 75 years old."
Could I join this clinical trial, if I wanted to?
"This trial is looking for 50 people, aged 18-75, who currently suffer from sick headaches. In order to qualify, participants must also meet the following criteria: A) At least 5 episodes of vestibular symptoms of moderate or severe intensity, lasting 5 min to 72 hours, B) Current or previous history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD), At least 5 episodes of vestibular symptoms of moderate or severe intensity, lasting 5 min to 72 hours, Headache with at least two of the following characteristics: one sided location, pulsating quality, moderate or severe"
Could you please summarize any risks associated with Galcanezumab Prefilled Syringe?
"Galcanezumab has been evaluated in Phase 2 clinical trials, meaning that while there is safety data, there is no information regarding the medication's efficacy."
Share this study with friends
Copy Link
Messenger